Yize Mao

1.3k citations
40 papers · 874 indexed · 1 hit paper · h-index 16

Yize Mao

35 papers receiving 864 citations

Hit Papers

Interferon-dependent SLC14A1+ cancer-associated fibroblas...14620222026202320244080120

Peers

Yize Mao
Comparison fields: 5 of 87
  • Oncology 537
  • Cancer Research 113
  • Immunology 133
  • Clinical Psychology 113
  • Surgery 234
Replace Marco Fornili with:
Marco Fornili Italy
Hyun‐Jeong Shim South Korea
Sumati Gupta United States
Nicole Burchardi Germany
Anthony Turpin France
Tao Wei China
Christina Moon United States
Patrick Imesch Switzerland
Catherine Parker United States
Yize Mao relative to Marco Fornili Italy Marco Fornili's profile →
Citations per field
00.5×3.4×
Marco Fornili · 1×
Citations per year

Countries citing papers authored by Yize Mao

Since Specialization
Citations

This map shows the geographic impact of Yize Mao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yize Mao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yize Mao more than expected).

Fields of papers citing papers by Yize Mao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yize Mao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yize Mao. The network helps show where Yize Mao may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yize Mao, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yize Mao Line = papers co-authored together Yize Mao links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20250
2 20250
3 202414
4 20236
5 202313
6 20225
7 20224
8 20211
9 2020200
10 202019
11 202016
12 20186
13 201815
14 201816
15 201832
16 201828
17 201719
18 201723
19 201610
20 201615

About Yize Mao

Yize Mao is a scholar working on Oncology, Otorhinolaryngology, Immunology, Hepatology and Radiology, Nuclear Medicine and Imaging, having authored 40 papers that have together received 874 indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (16 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (8 papers), Radiomics and Machine Learning in Medical Imaging (7 papers), Inflammatory Biomarkers in Disease Prognosis (6 papers), Neuroendocrine Tumor Research Advances (4 papers), Cancer Immunotherapy and Biomarkers (4 papers), Pancreatitis Pathology and Treatment (4 papers) and Immune cells in cancer (4 papers). The work is most often cited by research in Oncology (537 citations), Cancer Research (113 citations), Immunology (133 citations), Clinical Psychology (113 citations) and Surgery (234 citations). Yize Mao has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Zikun Ma, Zhuowei Liu, Shengping Li, Chaobin He, Shengping Li, Xin Huang, Wei Chen, Chaofeng Li, Zhizhou Duan and Guo‐He Lin. Their work appears in journals such as Nature Communications, European Radiology, Cancer Medicine, Journal of Gastrointestinal Surgery and Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026